InflammaGen Begins Clinical Trial of Treatment for Multi-Organ Failure
publication date: Mar 15, 2012
InflammaGen™ Therapeutics, a San Diego clinical-stage company, will start a 200-patient Phase II trial in the US of its InflammaGen Shok-Pak as a treatment and prevention of multi-organ failure (MOF). To develop the product outside the US, InflammaGen has retained ChinaBio® to assist the company with its efforts to bring Shok-Pak to China. ChinaBio has several similar engagements underway with other US and European companies, helping them secure co-development partners and funding in China for their clinical stage assets. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.